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Abstract: Candida infections continue to play a significant role not only in critically ill and 
immunocompromised patients but also in non-compromised patients. The incidence of systemic 
fungal infections in the United States has been on the rise for the past 30 years. Anidulafungin and 
all echinocandins inhibit glucan synthase thus inhibiting the formation of 1,3-β-D-glucan which is 
an essential component of the fungal cell wall. The decrease in 1,3-β-D-glucan results in the osmotic 
lysis of the cell, resulting in fungicidal activity against candida. Anidulafungin is active against most 
species of candida and resistance to it is very rare. Two potential mechanisms conferring reduced 
susceptibility to the echinocandins are efflux and target alteration. The efflux pump associated with 
fluconazole resistance in Candida albicans can confer higher minimum inhibitory concentrations 
to caspofungin. The second mechanism of resistance is via mutations in the genes which code for 
1,3 β-D-glucan synthase, specifically FKS1. Because of its spectrum of activity, fungicidal nature, 
and tolerability it is an attractive first-line therapeutic choice for treating candidemia in both non-
neutropenic and neutropenic patients. Because it is available only parenterally its role in treating 
mucocutaneous candidiasis is primarily in patients unable to take oral therapy.
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Candida infections continue to play a significant role not only in critically ill and 
immunocompromised patients but also in non-compromised patients. The spectrum of 
disease caused by candida ranges from non-life-threatening mucocutaneous infections 
to life-threatening invasive candidiasis/candidemia. Candida remains the 4th and 5th 
leading cause of bloodstream infections in adult and pediatric patients, respectively.1,2 
The incidence of systemic fungal infections in the United States has been on the rise 
the past 30 years. Between 1979 and 2000 the annual number of sepsis cases due to 
fungal organisms increased by 207%.3 In addition the number of candida-related hos-
pitalizations increased by 52% between 2000 and 2005.4 Common risk factors for the 
development of systemic candidiasis or candidemia include: immunosuppression, use 
of broad-spectrum antibiotics, central venous catheters, TPN, disruption of mucosal 
membranes and extremes of age.5
The echinocandin class of anti-fungal agents (anidulafungin, caspofungin, and 
micafungin) was introduced into the United States and European markets in 2001. 
They are the most recent addition joining the azoles, polyenes, allylamines, and anti-
metabolites available for treating systemic fungal infections. The echinocandins are 
recommended as potential first-line therapy for candidemia in non-neutropenic and 
neutropenic patients and first- or second-line for several other candida infections.6 Infection and Drug Resistance 2009:2 52
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This review will focus on anidulafungin and its role in 
candida infections.
Chemistry
The echinocandins are synthetically modified lipopeptides 
which were identified from the fermentation broths of 
various fungi. Anidulafungin (Figure 1) is derived from 
Aspergillus nidulans. It is a 1-[(4R,5R)-4,5-Dihydroxy-
N2-[[4′′ (pentyloxy)[1,1′:4′,1′′-terphenyl]-4-yl]carbonyl]-
L-ornithine]echinocandin B. Its molecular formula is 
C58H73N7O17, and its molecular weight is 1140.3.7 The echi-
nocandins are only available parenterally and anidulafungin 
is available in both 50 and 100 mg vials.
Anidulafungin is initially reconstituted with a diluent 
containing 20% (w/w) dehydrated alcohol in water for 
injection and then diluted to its final concentration of either 
0.36 or 0.43 mg/mL in either 5% dextrose or normal saline. 
Compatibility studies with other diluents or solutions have 
not been performed therefore they should not be used. The 
maximum rate of infusion for anidulafungin is 1.1 mg/min. 
Histamine-related adverse effects such as rash, urticaria, 
flushing, pruritus, dyspnea, and hypotension have been 
reported when the infusion rate exceeds 1.1 mg/min.7
Mechanism of action, FDA-approved 
indications and dosing
Anidulafungin and all echinocandins inhibit glucan synthase 
thus inhibiting the formation of 1,3-β-D-glucan which is 
an essential component of the fungal cell wall. Glucan 
synthase is present in fungal cells but not mammalian cells. 
The decrease in 1,3-β-D-glucan results in the osmotic lysis 
of the cell, resulting in fungicidal activity against candida.8 
Anidulafungin is FDA approved for the treatment of 
esophageal candidiasis, candidemia, and invasive candidiasis 
(intra-abdominal abscess and peritonitis).7
For the treatment of esophageal candidiasis, the recom-
mended loading dose is 100 mg followed by the maintenance 
dose of 50 mg daily. The duration of treatment should be 
based on the patient’s clinical response with most patients 
being treated for 14 days, or for 7 days after the reso-
lution of symptoms. For the treatment of candidemia, the 
recommended loading dose of 200 mg is followed by 100 mg 
daily for the duration of treatment of 14 days after the 
last positive blood culture results. No dosage adjustments 
are needed in patients with hepatic or renal impairment 
regardless of severity. Anidulafungin is not dialyzed during 
hemodialysis.7
Spectrum of activity
The Clinical and Laboratory Standards Institute (CLSI) 
established susceptibility breakpoints for the echinocandins 
in 2007. The breakpoint for susceptible against Candida 
organisms is 2 mg/mL for all three echinocandins and 
given the extremely low number of isolates with minimum 
inhibitory concentrations (MICs) higher than 2 mg/mL no 
breakpoints for intermediate or resistant were established.9 
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Figure 1 Anidulafungin chemical structure.Infection and Drug Resistance 2009:2 53
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Organisms  with  MICs    2 mg/mL  are  considered 
non-susceptible. The European Committee for Antimicrobial 
Susceptibility Testing (EUCAST) has not established 
breakpoints for the echinocandins.10 The organisms to which 
the echinocandins are highly active include C. albicans, 
C. glabrata, C. tropicalis, C. dubliniensis, and C. krusei. 
In general, the MIC50 of anidulafungin against these pathogens 
is 0.03 mg/mL and the MIC90 is 0.13 mg/mL.11,12 In vitro 
anidulafungin is more active than caspofungin against these 
pathogens although this has not been clinically proven 
to be significant.11–14 The echinocandins are less active 
against C. parapsilosis, C. guilliermondii, and C. lusitaniae 
compared to the other Candida spp; the MIC50 and MIC90 
of anidulafungin range from 0.06 to 2 and 0.25 to 2 mg/mL, 
respectively.11–13 Anidulafungin is highly active against 
azole-resistant candida with 99% of isolates inhibited 
at 1 mg/mL.11 CLSI recommends further testing be 
performed on C. albicans, C. tropicalis, or C. glabrata 
isolates in which an echinocandin MIC of 1 or 2 mg/mL 
is obtained. None of the echinocandins are active against 
Cryptococcus neoformans (MICs 16 to 64 mg/mL) or 
other Cryptococcus spp.15 The echinocandins are active 
against Aspergillus spp.16–20 The MIC90 for anidulfungin 
against A. fumigatus is 0.25 mg/mL.16,17 Activity against 
other species of Aspergillus is similar to that seen against 
fumigatus.
Resistance
Resistance to the echinocandins is rare amongst Candida 
spp. and identification of the mechanism(s) has resulted 
in contradictory information. The efflux pump associated 
with fluconazole resistance in C. albicans was suggested to 
confer higher MICs to caspofungin.21 The increase in MICs to 
caspofungin was minor and the isolates were still considered 
susceptible by CLSI breakpoint. This cross-substrate of the 
echinocandins to the fluconazole efflux pump did not occur 
with all yeast isolates expressing or hyperexpressing the 
efflux pump.22 The second mechanism of resistance to the 
echinocandins in C. albicans, C. parapsilosis and C. krusei 
is via mutations in the genes which code for 1,3 β-D-glucan 
synthase, specifically FKS1.23–25 Five candida isolates, 
which had MICs  4 mg/mL to caspofungin were recovered 
from patients enrolled in a caspofungin clinical trial and all 
were found to have mutations in the FKS1 gene.23 Within 
C. parapsilosis an intrinsic mutation in FKS1 appears to be 
responsible for the higher MICs for the echinocandins. The 
mutations in the conserved hot spot 1 region of fks1 appear 
to result in a glucan synthase which is less sensitive to the 
echinocandins and some isolates had MICs  8 mg/mL.26–28 
Another study failed to demonstrate mutations in the hot 
spot 1 of several isolates of C. parapsilosis which had higher 
MICs to caspofungin.29 These isolates had caspofungin and 
micafungin MICs of 8 mg/mL and the anidulafungin MIC90 
for anidulafungin was 2 mg/mL. Moudgal and colleagues 
also reported a C. parapsilosis isolate in which the caspo-
fungin and micafungin MICs increased to 16 mg/mL while 
anidulafungin’s MIC was 2 mcg/mL.30 The mechanism 
behind this disparity in MICs of anidulafungin compared to 
the other 2 agents is still unknown but mutations in FKS2 
and/or FKS3 may play a role.
The incidence of developing resistance during therapy is 
still rare and a small number of cases regarding the develop-
ment of higher MICs while receiving caspofungin have been 
reported. The first involved C. parapsilosis prosthetic valve 
endocarditis and the patient failed caspofungin therapy. The 
MICs during the first hospitalization were 2, 8 and 1 mg/mL 
for caspofungin, micafungin and anidulafungin, respectively 
which increased to 16 mg/mL for caspofungin and mica-
fungin and 2 mg/mL for anidulafungin.30 Reports of failed 
echinocandin therapy in HIV or AIDS patients with recurrent 
esophagitis caused by C. albicans have been published.31–33 
Gene sequencing in two of the cases revealed C. albicans 
isolates with caspofungin MICs of  8 mg/mL with mutation 
of the FKS1 gene.31,32 One of the isolates was resistant to all 
3 of the echinocandins.32 Reports exist as well for other non-
albicans candida (C. glabrata, C. krusei and C. tropicalis) 
developing resistance during caspofungin therapy.34–36 
Increases in MICs to the three echinocandins are not neces-
sarily uniform as demonstrated by these case reports.
Potential limitations or problems with the current CLSI 
breakpoint of 2 mg as susceptible and the methodologies 
recommended for susceptibility testing by both CLSI and 
EUCAST have been identified. Ardendrup and colleagues 
evaluated susceptibility methodologies on a C. albicans 
isolate from a patient who died from a fungal infection 
which had been treated with caspofungin.37 In addition 
to the EUCAST38,39 and CLSI40 methods they evaluated 
Etest and agar dilution susceptibility methods. The 
EUCAST method resulted in a susceptible interpretation 
for both caspofungin and anidulafungin with MICs 
of 2 and 0.125 mg/mL, respectively. The CLSI 
method resulted in caspofungin and anidulafungin MICs 
of 2 and 0.5 mg/mL, respectively. Etest demonstrated 
MICs for both agents of 32 mg/mL and agar dilution 
showed growth at all dilutions including 2 mg/mL. Molecular 
characterization of  the isolate revealed a mutation in the hot Infection and Drug Resistance 2009:2 54
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spot region of the FKS1 gene.37 It has been demonstrated 
that in the presence of serum the MICs of caspofungin 
increase an average of 1- to 16-fold, micafungin 32- to 
128-fold, and anidulafungin 8- to 256-fold compared to 
testing conditions without serum.41,42 Garcia-Effron and 
colleagues evaluated the susceptibility of the echinocandins 
in the absence and presence of serum against 14 isolates 
with FKS1 mutation.43 CLSI and EUCAST methodologies 
don’t include serum in their methodologies and under these 
conditions 12/14 isolates were susceptible to anidulafungin, 
10/14 to micafungin, and only 3/14 to caspofungin. In the 
presence of serum 2/14 were susceptible to anidulafungin, 
1/14 to micafungin, and 0/14 to caspofungin.43 Therefore, 
current susceptibility testing methods may not detect all 
echinocandin non-susceptible candida isolates with the 
FKS1 mutation. Further evaluation is needed to determine if 
changing the breakpoint for micafungin and anidulafungin 
is warranted to detect non-susceptible candida organisms. 
In addition there is a need to further evaluate the role of 
including serum in the methodologies for susceptibility 
testing as well as how to interpret the data. At present, 
Garcia-Effron and colleagues postulate that caspofungin 
can be used as a surrogate marker for predicting the sus-
ceptibility of all of the echinocandins based on the premise 
that the echinocandins share the same target, mechanism of 
resistance, spectrum of activity and in vitro potency.43
Pharmacodynamics
Results from four phase 2 and 3 studies of anidulafungin in 
patients with esophageal or oropharyngeal candidiasis were 
examined to determine a pharmacokinetic-pharmacodynamic 
relationship. In this study, successful treatment was defined 
as either resolution of signs and symptoms or endoscopic 
response at the completion of therapy. Multiple pharmacoki-
netic parameters were associated with success and included 
the AUC at steady state (AUCss) greater than 35 mg*h/L, 
concentration at steady state (Css) greater than 1.5 mg/mL, 
and minimum concentration (Cmin) greater than 1 mg/mL. 
This study did not specify which of these pharmacokinetic 
parameters was most closely associated with success. 
Anidulafungin’s potent activity against Candida spp. and 
its favorable pharmacokinetics allow drug exposure to be in 
excess of these pharmacokinetic-pharmacodynamic targets 
with recommended doses. Anidulafungin at the approved 
maintenance dosage of 50 mg per day for esophageal candi-
diasis produces a Css of 2.2 mg/mL, an AUCss of 53 mg*h/L 
and a Cmin above 1 mg/mL throughout the dosing interval in 
a typical patient.44
Similar findings were also reported in animal studies. 
When a pharmacokinetic-pharmacodynamic relationship 
was evaluated in persistently neutropenic rabbit infection 
model with disseminated candidiasis, 100% efficacy was 
achieved with a Cmax of approximately 2 mg/mL, an AUC0–24 
of 8 mg*h/mL, and a time of 12 hours with plasma concentra-
tion above the minimum fungicidal concentration (MFC) for 
the test organism. Again, this model was not able to discern 
which parameter most closely associated with optimal anti-
fungal activity.45 Another study of pharmacodynamic char-
acterization in a neutropenic murine model of disseminated 
candidiasis reported concentration-dependent efficacy against 
C. albicans and C. glabrata. In this study, the Cmax:MIC and 
the AUC0–24:MIC ratios were most strongly associated with 
antifungal activity.46 A post anti-fungal effect (PAFE) exists 
for the echinocandins and candida. Against Candida spp., the 
PAFE is concentration-dependent with higher concentrations 
resulting in longer PAFEs.47,48 At concentrations equal to or 
greater than the MIC of the Candida organism the PAFE was 
greater than 12 hours for most isolates tested.47,48
An Eagle effect is an in vitro paradoxical effect, and above 
a particular concentration instead of a decrease in organism, 
an increase occurs. This effect has been observed with the 
echinocandins with both yeast and filamentous fungi.49–51 
Stevens and colleagues postulated that the high concentra-
tions derepressed resistance mechanisms.52 The clinical 
significance of this phenomenon is unknown but appears to 
be negligible and further evaluation may be warranted.
Pharmacokinetics
Pharmacokinetic studies of  anidulafungin have been conducted 
in healthy volunteers, patients with invasive fungal infection, 
renal or hepatically impaired patients, and in children. Results 
from these studies demonstrate that anidulafungin has poor 
and variable absorption after oral administration. However, 
when administered intravenously, absorption concentrations 
are predictable and exposure is increased linearly with dose.
Pharmacokinetics in healthy volunteers
The pharmacokinetics of [14C] anidulafungin at a mean dose 
88.3 mg (range: 87.6 to 88.7 mg) and 95 mg Ci were evalu-
ated in 9 healthy male volunteers. Following a single intra-
venous dose of anidulafungin, a mean Cmax of 3.63 mg/mL, 
mean AUC of 92.5 mg*h/mL, a large volume of distribution 
(Vd) of 32.6 L and a long-mean terminal elimination half-life 
(t1/2) of 27.7 hours were reported.53
In addition to the aforementioned pharmacokinetic study 
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degradation, in vitro human cytochrome P450 inhibition, in 
vitro incubation with rat and human hepatocytes, and mass 
balance studies in rats were conducted to characterize anidu-
lafungin clearance. The results revealed that anidulafungin 
undergoes slow chemical degradation to a primary inactive 
product, which is likely further degraded by plasma pepti-
dases. The primary degradation product and subsequent ones 
produced by plasma peptidases are assumed to be void of 
antifungal activity. The products from degradation and less 
than 10% of the unchanged drug are eliminated into feces 
via biliary excretion. Although the intact drug has a t1/2 of 
approximately 1 day, the degradation products are thought 
to persist in the body for a longer period of time. Anidula-
fungin does not undergo hepatic metabolism nor interact 
with cytochrome P450 isoenzymes. Renal elimination of 
the drug is negligible.53
Pharmacokinetics in patients  
with invasive fungal infections
Data from four different phase 2 and 3 clinical studies were 
combined to describe the pharmacokinetic characteristics 
of anidulafungin in patients with invasive fungal infections. 
A total of 225 patients received various anidulafungin 
regimens consisting of a loading dose of twice the daily main-
tenance dose (50, 75, 100 mg) as treatment for esophageal 
candidiasis (129 patients), invasive candidiasis (87 patients), 
invasive aspergillosis (7 patients) or azole-refractory mucosal 
candidiasis (2 patients). All doses were administered intra-
venously at a rate of 1 mg/min.54
The results revealed that a two-compartment model 
with first-order elimination best described the disposition 
of anidulafungin. The estimated pharmacokinetic param-
eters were similar to those observed in healthy volunteers. 
The clearance was estimated to be 0.946 L/h, the Vd at 
steady state was 33.2 L, and the t1/2 was 25.9 hours. When 
demography (age, sex, weight, race), concomitant drugs, 
and study participation were taken into consideration, the 
central volume of distribution increased with increasing 
body weight. In addition, clearance was increased in male 
subjects, patients with increased body weight and patients 
who participated in the invasive candidiasis study. Patients in 
the invasive candidiasis study were hospitalized, older, had 
higher body weight, and were more acutely ill than those who 
participated in the esophageal candidiasis study which may 
have contributed to altered clearance of the drug. However, 
these predictors explained less than 20% of the difference 
in clearance rate and the differences were deemed to have 
little clinical significance.54
Concomitant medications that were categorized as 
substrates, inducers, or inhibitors of cytochrome P450 
isoenzymes, including rifampin were also evaluated in 
this study. None of these drugs had significant impact on 
anidulafungin population pharmacokinetic parameters, 
indicating lower potential for interactions with drugs that 
affect cytochrome P450 isoenzymes.54
Renal and hepatic impairment
To evaluate anidulafungin pharmacokinetics in patients with 
hepatic insufficiency, a single intravenous dose of 50 mg was 
administered to 19 subjects (6 mild, 6 moderate, and 7 severe 
hepatic impairment patients). Pharmacokinetic parameters in 
patients with mild or moderate impairment were not signifi-
cantly different from healthy controls. On the other hand, 
subjects with severe hepatic impairment showed statistically 
significant decreases in Cmax (36% decrease: mean ± SD 
1.8 ± 0.8 vs 2.9 ± 0.7 mg/mL) and AUC (33% decrease 
46.6 ± 14.1 vs 70.0 ±13.4 mg*g/mL) as well as, significant 
increases in clearance (57% increase: 1.16 ± 0.34 vs 
0.74 ± 0.15 L/h) and volume of distribution at steady state 
(78% increase: 50.8 ± 17.0 vs 28.5 ± 6.5 L). However, the 
half-life was similar in both groups (severe hepatic impair-
ment vs controls: 35.2 ± 7.1 vs 31.2 ± 1.5 hours). This 
decrease in exposure compared with control subjects were 
thought to be due to ascites and edema. Unfortunately, protein 
binding was not evaluated in this study. The reduced Cmax 
and AUC in these patients may be important factors to con-
sider in the treatment of fungemia. However, anidulafungin 
50 mg per day produces levels that exceed the MIC90 of most 
Candida spp. throughout the dosing period. Consequently, 
no dosage adjustment of anidulafungin is currently recom-
mended for any degree of hepatic impairment.55
Anidulafungin’s pharmacokinetic profile was evaluated 
in 21 patients with varying degrees of renal function. Patients 
with mild (51 to 70 mL/min), moderate (31 to 50 mL/min), 
severe (30 mL/min) renal impairment or patients with 
end-stage renal disease were given a single 50 mg dose 
of anidulafungin. In comparison to 8 healthy volunteers, 
pharmacokinetic profiles were similar among the groups. 
In addition, no measurable quantity of anidulafungin was 
present in dialysate. Therefore, due to minimal renal excre-
tion and clearance by hemodialysis, no dosage adjustment of 
anidulafungin is needed in renal insufficiency.55
Pediatric pharmacokinetics
The pharmacokinetic profile of anidulafungin was studied in 
immunocompromised, hospitalized children with neutropenia. Infection and Drug Resistance 2009:2 56
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Children aged 2 to 17 years were given either a loading 
dose of 1.5 mg/kg (maximum 100 mg) followed by 
0.75 mg/kg per day (maximum 50 mg) or a loading dose 
of 3 mg/kg (maximum 200 mg) followed by 1.5 mg/kg per 
day (maximum 100 mg). The mean duration of therapy was 
8.7 days (range of 1 to 23 days). As with adults, steady-sate 
concentration was achieved after the loading dose. Similar 
concentration profile is reported in pediatric patients receiv-
ing doses of 0.75 mg/kg per day and adults receiving 50 mg 
per day as well children receiving 1.5 mg/kg per day and 
adults 100 mg per day. The half-life was approximately 
20 hours which was slightly less than those estimated in 
adults, but still supports once daily dosing. Body weight 
affected clearance and volume of distribution. Therefore, 
for children aged 2 years and older, anidulafungin should 
be dosed based on body weight and no dosage adjustment 
is recommended based on age.56
Clinical trials
esophagitis
One randomized, double-blind, non-inferiority trial compar-
ing anidulafungin to fluconazole therapy was assessed for 
esophageal candidiasis.57 Anidulafungin 100 mg loading dose 
followed by 50 mg once daily (n = 249 evaluable patients) 
and was compared to fluconazole 200 mg loading dose fol-
lowed by 100 mg once daily (n = 255 evaluable patients). 
The endoscopic success rates at the end of therapy (EOT) 
for anidulafungin and fluconazole were 97.2% and 98.8%, 
respectively. The clinical success rates were 98.8% for anidu-
lafungin 99.6% for fluconazole. The endoscopic exam at the 
2-week follow-up of 462 patients revealed a success rate of 
64.4% for anidulafungin compared to 89.5% for fluconazole 
which was statistically significant.57
A phase 2 open-label trial of anidulafungin for the 
treatment of azole-refractory mucosal candidiasis was 
performed.58 Nineteen patients were enrolled and received 
anidulafungin 100 mg loading dose followed by 50 mg once 
daily. Seventeen of 18 patients (94%) of patients with oropha-
ryngeal candidiasis and 11/12 patients (92%) with esophageal 
candidiasis achieved clinical success at the end of therapy. 
The clinical success at the 10- to 14-day follow-up was 
8/18 (44%) with oropharyngeal candidiasis and 6/12 patients 
(50%) with esophageal candidiasis.58
Candidemia/invasive candidiasis
Two studies evaluating the efficacy of anidulafungin for 
candidemia or invasive candidiasis have been performed. 
The first was a randomized, dose ranging study in adult 
patients with doses of 50 mg, 75 mg, or 100 mg once daily 
of anidulafungin.59 In the modified-intent-to-treat (MITT) 
analysis there were 37, 40, and 39 patients in the 50 mg, 
75 mg, and 100 mg dosing groups, respectively. A load-
ing dose of twice the maintenance dose was administered 
on day 1 in each dosage group. Candidemia was the most 
prevalent infection occurring in 94% of patients, 10% 
(12 patients) had positive tissue cultures, 4% (5 patients) had 
both positive tissue and blood cultures, and 1 patient had a 
prosthetic hip infection. C. albicans accounted for 53% of 
the infections followed by C. glabrata (31%), C. tropicalis 
(9%), C. parapsilosis (9%), C. krusei (4%), then others at 
3%. Global response was defined as both clinical and micro-
biological success and was assessed at EOT and follow-up. 
At EOT the global response for the 83 evaluable patients 
was 84%, 90%, and 89% with the 50 mg, 75 mg, and 100 mg 
doses, respectively. At follow-up, the global response of the 
68 evaluable patients decreased to 72%, 85%, and 83% with 
the 50 mg, 75 mg, and 100 mg doses, respectively.59
The second study was a randomized, prospective, non-
inferiority study comparing anidulafungin to fluconazole 
for candidemia or invasive candidiasis.60 Patients aged 16 to 
91 years received either 200 mg on day 1 followed by 100 mg 
once daily of anidulafungin or 800 mg on day 1 followed 
by 400 mg once daily of fluconazole for at least 14 days 
from improvement of symptoms and negative cultures. The 
primary outcome was a successful global response which 
was defined as both clinical success (resolution of signs and 
symptoms of invasive candidiasis and no need for additional 
systemic antifungal therapy) and microbiologic success 
(eradication of candida species present at baseline which was 
determined on follow-up culture or the presumed eradica-
tion if cultures were not available) at the end of intravenous 
therapy. Secondary outcomes were global response at the end 
of all therapy, 2 and 6 weeks follow-up. In the MITT analysis 
127 patients received anidulafungin and 118 received fluco-
nazole. Candidemia was the most prevalent infection occur-
ring in 116/127 (91.3%) of patients receiving anidulafungin 
and 103/118 (87%) of patients receiving fluconazole. Seven 
(6%) and 11 patients (9%) had candida recovered from other 
sterile body fluids or sites in the anidulafungin and fluco-
nazole groups, respectively. Three percent in both groups 
had candida in both the blood and a sterile site. C. albicans 
was the predominant pathogen in patients receiving either 
anidulafungin (64%) or fluconazole (59%). The other 
pathogens in the anidulafungin arm were C. glabrata (16%), 
C. tropicalis (12%), C. parapsilosis (10%). The pathogens 
in the fluconazole arm were slightly different in frequency Infection and Drug Resistance 2009:2 57
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with C. glabrata (25%), C. tropicalis (9%), C. parapsilosis 
(14%), however this was not statistically different. A suc-
cessful global response at the end of intravenous therapy 
was 75.6% (96/127 patients) in the anidulafungin arm and 
60.2% (71/118 patients) in the fluconazole arm which was 
statistically significant. Anidulafungin demonstrated higher 
successful global response than fluconazole at each of the 
secondary assessments: EOT (74.0% vs 56.8%), 2-week 
follow-up (64.6% vs 49.2%), and 6-week follow-up (55.9% 
vs 44.1%) although at 6 weeks the difference was not 
statistically significant. Mortality was higher in the patients 
receiving fluconazole (37/118, 31.4%) than anidulafungin 
(29/127, 22.8%) however this was not significant. In addi-
tion, more patients died in the first 10 days in the fluconazole 
arm (14) compared to 5 in the anidulafungin group. This 
study demonstrated anidulafungin was more efficacious 
than fluconazole at end of intravenous therapy for treating 
candidemia/invasive candidiasis. A curiosity of the study is 
the clinical response rates for C. albicans and C. glabrata. 
In the anidulafungin arm the success rates were 81.1% and 
56.3% for albicans and glabrata, and in the fluconazole arm 
were 62.3% and 50%, respectively. It appears the primary 
difference in global response was due to the poor response 
in fluconazole treated patients infected with C. albicans. One 
study site enrolled 25 patients which accounted for 10% of 
the MITT population. Fifteen patients received anidulafungin 
and 14 had a successful global response and only 5 of the 
10 patients who received fluconazole had a successful 
global response. Statistical analysis did not reveal a study 
site bias. However, if those 25 patients are removed from 
the analysis then there is no difference in global response 
between the two therapies. According to FDA guidelines, 
a second study demonstrating this exceptional outcome of 
anidulafungin over fluconazole would be required in order 
to prove superiority.
Invasive candidiasis/candidemia  
in neutropenic patients
In a neutropenic mouse model of invasive candidiasis, 
anidulafungin demonstrated good activity against 3 strains 
of C. glabrata; 1 was resistant to fluconazole and 1 was 
resistant to amphotericin B.61 Clinical trials with anidula-
fungin enrolled so few patients with neutropenia that no 
assessment could be made therefore anidulafungin does not 
have a FDA indication for treating candidemia or invasive 
candidiasis in neutropenic patients. Despite this lack of 
indication the Infectious Diseases Society of America has 
recommended anidulafungin as a potential first-line therapy 
for the treatment of candidemia in neutropenic patients.6 
However, anidulafungin is not indicated in the guidelines 
for the empiric treatment of suspected invasive candidiasis 
in neutropenic patients, nor is it recommended for prophy-
laxis for solid-organ transplant recipients, patients hospital-
ized in intensive care units, neutropenic patients receiving 
chemotherapy, and stem cell transplant recipients at risk of 
candidiasis.6
Drug interactions
Anidulafungin is neither a substrate nor an inhibitor of the 
cytochrome P450 enzyme system or of P-glycoprotein. 
Therefore, it is unlikely that anidulafungin will alter the 
pharmacokinetics of drugs that influence cytochrome 
P450 isoenzymes or be affected by them. Several studies 
evaluated the influence of anidulafungin on the metabolism of 
rifampin, cyclosporine, tacrolimus liposomal amphotericin B 
and voriconazole. These investigations do not report any 
significant alterations in the pharmacokinetics of either the 
tested agent or of anidulafungin.
Rifampin
In the aforementioned population pharmacokinetic study, 
concomitant medications taken by 225 patients were 
categorized as substrates, inducers, or inhibitors of cyto-
chrome P450 and evaluated for their effect on clearance of 
anidulafungin. Rifampin is a potent inducer and therefore, 
was evaluated separately. A total of 27 patients (12%) were 
taking rifampin during the study. Anidulafungin clearance 
was not affected by concomitant treatment with substrates, 
inhibitors, or inducers of the cytochrome P450 isoenzymes, 
including rifampin.54
Cyclosporine
The interaction of anidulafungin and cyclosporine was 
evaluated in 12 healthy volunteers. Subjects were given 
anidulafungin 200 mg on day 1 then 100 mg once daily 
intravenously on days 2 to 8 and cyclosporine 1.25 mg/kg 
orally twice daily on days 5 to 8. One subject was withdrawn 
from the study on day 6 due to slight increases in hepatic 
transaminase levels. After concomitant administration of 
cyclosporine, the mean AUC of anidulafungin was 22% 
higher, the mean Cmin was 43% higher, the clearance was 16% 
lower. These alterations in anidulafungin pharmacokinetics 
were not considered clinically significant and subsequently, 
no dosage adjustments were recommended. The effect of 
anidulafungin on cyclosporine pharmacokinetics was not 
evaluated in this study.62Infection and Drug Resistance 2009:2 58
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Tacrolimus
The potential interaction between anidulafungin and 
tacrolimus was evaluated in 36 healthy male volunteers. 
Subjects received tacrolimus 5 mg orally on days 1 and 
13 and anidulafungin 200 mg on day 4 followed by 100 mg 
once daily intravenously on days 5 to 13. There were no sig-
nificant differences in any of the pharmacokinetic parameters 
measured with or without co-administration of tacrolimus 
and anidulafungin. Therefore, no dosage adjustment is 
recommended.63
Liposomal amphotericin B
The effect of  co-administration of anidulafungin and liposomal 
amphotericin B was evaluated in 17 patients with invasive 
aspergillosis. Anidulafungin (100 mg once daily) and lipo-
somal amphotericin B (5 mg/kg per day) were administered 
concurrently until resolution of signs or symptoms of aspergil-
losis or for a total of 90 days. Co-administration of these two 
antifungal agents was well tolerated by all subjects.64
voriconazole
A combination of anidulafungin and voriconazole was evalu-
ated in 17 healthy male volunteers. In a blinded, random-
ized, crossover design, subjects received anidulafungin with 
placebo, voriconazole with placebo, and anidulafungin with 
voriconazole. Voriconazole was administered orally 400 mg 
every 12 hours on day 1 followed by 200 mg every 12 hours 
on days 2 to 4. Anidulafungin was given intravenously 
200 mg on day 1 followed by 100 mg per day on days 2 to 4. 
There were no significant differences in pharmacokinetic 
parameters when subjects received anidulafungin alone or 
in combination with voriconazole or voriconazole alone or 
in combination with anidulafungin. Co-administration of 
anidulafungin and voriconazole was well tolerated.65
Safety
Anidulafungin is well tolerated with few adverse effects. 
Abnormal liver function tests and hypokalemia are the 
most commonly reported adverse effects at 1.5% to 5% and 
3% to 10%, respectively. Nausea, vomiting, and diarrhea 
have also been reported in 1% to 3% of patients.57,59,60 
Histamine-related adverse effects such as rash, urticaria, 
flushing, pruritus, dyspnea, and hypotension have been 
reported when the infusion rate exceeds 1.1 mg/min.7
Summary
Anidulafungin is active against most species of candida 
and resistance to it is very rare. Because of its spectrum of 
activity, fungicidal nature, and tolerability it is an attractive 
first-line therapeutic choice for treating candidemia in both 
non-neutropenic and neutropenic patients. Because it is 
available only parenterally its role in treating mucocutaneous 
candidiasis is primarily in patients unable to take oral therapy. 
Further studies are needed to define the role of anidulafungin 
in the empiric treatment of suspected invasive candidiasis in 
neutropenic patients, or other immunocompromised patients, 
candida osteomyelitis, meningitis, and endocarditis.
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